This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): GLP-Fc Analog, LY2189265, Torurishiti (JP)
Description: Trulicity is a fusion protein consisting of a long-acting analogue of glucagon-like peptide 1 (GLP-1) linked to the constant heavy chain (Fc) portion of an immunoglobulin (IgG4). The drug has once-weekly dosing.
It is administered using an autoinjecter with a small gauge (29 G) needle and injection volume of 0.5 mL.
GLP-1 is an incretin hormone secreted in the small intestine and colon in response to food intake. It enhances insulin secretion when glucose levels are high, suppresses inappropriate glucagons secretion (glucagon has the opposite effect of insulin), slows gastric emptying (slowing entry of ingested nutrients into the bloodstream, hence limiting post-prandial glucose), and via actions on the brain is thought to promote satiety.
Revenue splits are BioMedTracker estimates.
Eli Lilly and Sumitomo Dainippon
In July 2015, Eli Lilly Japan and Sumitomo Dainippon Pharma announced that the two companies signed a sales collaboration agreement for a once-weekly GLP-1 receptor agonist Trulicity Subcutaneous Injection 0.75 mg Ateos. Based on this agreement, Eli Lilly Japan retains a manufacturing/marketing license for Trulicity and Sumitomo Dainippon Pharma takes responsibility for sales/distribution of the drug. Eli Lilly Japan and Sumitomo Dainippon Pharma will conduct activities to provide healthcare professionals with information regarding Trulicity.
Partners: Sumitomo Dainippon Pharma Co., Ltd.
Additional information available to subscribers only: